Ritesh Patel

Title: Ritesh Patel and a Fixed-Dose Diabetes Treatment

Introduction

Ritesh Patel is an inventor based in Ahmedabad, India, and is associated with Unison Pharmaceuticals Pvt. Ltd. His patent work concerns pharmaceutical formulations intended to support diabetes treatment.

Latest Patents

Patel is identified with one patent, titled “Pharmaceutical Composition Comprising Combination of Sitagliptin and Empagliflozin.” The invention describes a stable fixed-dose composition combining a DPP-IV inhibitor with an SGLT2 inhibitor to help reduce blood glucose levels in patients with diabetes.

More specifically, the composition includes sitagliptin, or an acceptable salt, solvate, hydrate, or premix, together with empagliflozin or an acceptable salt, solvate, hydrate, or premix, and one or more pharmaceutically acceptable excipients. The patent also describes a formulation containing sitagliptin phosphate monohydrate and empagliflozin, with attention to content uniformity, reduced degradation impurities, and dissolution performance. Patel’s listed patent count is 1 patent.

Career Highlights

Patel’s documented innovation focuses on combining two diabetes medicines in a stable pharmaceutical formulation. His association with Unison Pharmaceuticals Pvt. Ltd. places this work within the pharmaceutical industry.

Collaborations

Patel’s listed coworkers include Balvir Singh and Ramesh Shingala. The available information identifies them as coworkers but does not specify their roles in the patent.

Conclusion

Ritesh Patel’s patent centers on a fixed-dose sitagliptin and empagliflozin formulation designed with stability, uniformity, impurity control, and dissolution in mind.